Pfizer Secures Ruling in Neurontin Class Action

Skadden achieved a favorable summary judgment ruling for Pfizer Inc in connection with claims brought by third-party payors and consumers related to the company’s alleged off-label marketing of the epilepsy medicine Neurontin. On December 10, the U.S. District Court for the District of Massachusetts granted Pfizer’s motion for summary judgment with respect to all third-party payors and all but two consumers.